Growing Inclination towards Leading Healthy Lifestyle to Bolster Global Microalbuminuria Market

San Francisco, California, November 29, 2018: The global market for microalbuminuria market is anticipated to witness a strong demand during the forecast period, 2017 – 2025, owing to incessant rise in diabetes and obesity cases all across the world. One of the main reason that is favoring the market is the substantial rise in consumption of fast foods, canned foods, packaged food, and ready-to-eat foods which have considerable amount of calories and fats in them. Rise in number of working class people throughout the world is one reason that has increased the consumption of these types of food, notices TMR Research. A report filed, “Microalbuminuria Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025”, in which the analysts have provided a complete overview of the market for readers to understand the complexities of the market. The report also offers several market dynamics such as opportunities, restraints, and trends which are expected to have a tremendous impact on the market in coming years.

Get Sample Copy of this Report @

Significant rise in the awareness among consumers regarding leading a healthy lifestyle is considered to be one factor that is expected to push the market in the forward direction. Growing inclination towards following a proper diet is foreseen to favor the market. Rise in spending power throughout the world is likely to catapult market growth. Apart from these aforementioned factors, entry of new players in the market is likely to give a competitive edge to the market, this will help to meet the rising demand of the market product. Major players in the market are focusing on research and development to produce better product and expand their product portfolios. Developing nations are increasing their expenditure to improve their healthcare infrastructure. This is anticipated to favor the market growth in years to come.

Read Comprehensive Overview of Report @

Microalbuminuria Market Expansion of newly developed products by 2025

Global Microalbuminuria Market: Snapshot

Microalbuminuria is a condition that affects the kidney and restricts in retaining serum albumin, which is considered as a vital factor for the kidney to maintain its overall health of the body. The rising cases of obesity of diabetes across the globe have resulted in a significant rise in the microalbuminuria, which is likely to encourage the growth of the market in the next few years. The rising emphasis of the leading players on the research and development activities and development of new products are expected to encourage the growth of the global microalbuminuria market in the coming years.

Furthermore, the rising awareness among consumers regarding a healthy lifestyle and diet and the increasing disposable income are projected to supplement the growth of the global microalbuminuria market in the next few years. In addition, the expected entry of new players in order to gain a competitive edge are likely to focus on the expansion of the product portfolio, which is estimated to supplement the market’s growth in the near future. At present, several tests are available in the market, which helps in determining the condition of microalbuminuria. The emergence of effective drugs and therapeutics is projected to contribute towards the development of the overall market.

Request Sample Copy of the Report @

The rising expenditure and the availability of enhanced healthcare infrastructure in developed economies are expected to generate promising opportunities for key players operating in Europe and North America. Furthermore, the presence of several leading players in these two regions are anticipated to accelerate the growth of the global microalbuminuria market in the next few years. This market is estimated to witness a healthy growth in several developing economies across the globe.

Global Microalbuminuria Market: Overview 

Albumin is a commonly found protein in the blood and constitutes around 50% of the blood protein. Microalbuminuria refers to a condition in which kidney is not able to retain serum albumin, which is essential for the kidney to maintain overall health of the body, and exerts it in the urine. During certain conditions like diabetes, especially type 1 patients, nephropathy, and other nephrotic syndromes, the chances of microalbuminuria is escalated. A research by British Medical Journal on diabetic children with type 1 diabetes revealed that 26% of the all the diabetic children had microalbuminuria, of which nearly 48% of the children had persistent microalbuminuria which is highly likely to lead to further worsening of the conditions in a few years.

Request TOC of the Report @

Though microalbuminuria can be treated in most causes with suitable treatment and medication along with dietary changes, certain cases can also be associated with high risk of ischemic heart disease. Consequently, routine monitoring and timely treatment of microalbuminuria is of utmost importance and as a result, the demand in the global market for microalbuminuria is projected for a healthy growth rate during the forecast period of 2017 to 2025.

Global Microalbuminuria Market: Trends and Prospects

Elderly people are more prone to diabetic diseases. According to the National Institute of Aging (NIH), 524 million people were aged over 65 across the globe and this number is estimated to reach 1.5 billion, which will represent nearly 16% of the world’s population. Moreover, the World Health Organization (WHO), 422 million people suffered from some form of diabeties in 2014, and the number is expected to continue swelling in the near future. These rising numbers are the foremost drivers in the global market for microalbuminuria.

Read Comprehensive Overview of Report @

Research and development for the treatment of microalbuminuria is another factor that is expected to favor the expansion of the market. As of now, the treatment is broadly via dietary supplements, but some manufacturers are also coming up with low fat or albumin variants. Since cholesterol or dyslipidemia treatment have not shown any effect on albuminuria patients, possibility for therapy for microalbuminuria is huge, before it turns into cardiovascular diseases. Increased disposable income among the urban population is also expected to boost the market in near future.

Global Microalbuminuria Market: Regional Outlook

Geographically, the global market for microalbuminuria treatment can be divided into North America, Asia Pacific, Europe, South America, and rest of the world. Currently, North America serves the maximum demand due to robust healthcare infrastructure in the countries such as the U.S. and Canada. However, regional markets of South and East Asia, Europe, South America, and Africa are also expected to extend the demand during the forecast period due to high prevalence rate of diabetic patients in these regions.

Some of the key players currently operational in microalbuminuria market are Novartis AG, Sanofi, Alfa Wassermann S.p.A, Steno Diabetes Center A/S, Takeda Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company, AstraZeneca Plc, AbbVie Inc. , Fondazione Mario Negri Sud, and Daiichi Sankyo Company, Ltd.

Microalbuminuria Screening as Reliable Marking for Diabetes Gaining Prominence

San Francisco, California, July 25, 2017: The growing significance of microalbuminuria as reliable and an independent predictor of cardiovascular disease and progressive renal disease has led to the constant evolution of the market. The rapidly increasingly burden of cardiovascular diseases worldwide and the rise in associated mortality and morbidity among adults, especially in developed nations, is a crucial trend boosting the microalbuminuria market. A new report penned by TMR Research, titled “Microalbuminuria Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017– 2025”, offers an elaborate assessment of various factors and trends influencing the growth of the market.

The research offers in-depth insights into the share and size of major trends, emerging diagnostics and therapies, research and development activities, recent technological advancements, and competitive landscape in various regions. The study tracks key clinical developments and studies related to albuminuria screenings in various populations groups and evaluates their impact on the emerging market dynamics. It also highlights major screening methods developed by prominent players.

The increasing clinical relevance of microalbuminuria as a key risk factor for the development of cardiovascular diseases and as a reliable marker of systemic endothelial dysfunction in general populations are significant factors catalyzing the market.

The relevance of microalbuminuria screening has gained particular significance in high-risk populations, those afflicted with systemic diseases such as diabetes and hypertension. This has clearly boosted the microalbuminuria market. In addition, the growing prevalence of prevalence of obesity, type 2 diabetes, and metabolic syndrome in children is a crucial trend catalyzing the growth of the market. In recent years, the screening for microalbuminuria among pediatric populations has gained some traction in the detection and prevention of cardiovascular disorders. This is expected to catalyze the microalbuminuria market growth.

In recent years, establishing of a close link between systemic endothelial dysfunction and vascular diseases have stimulated researches in the market. Furthermore, evaluation of the pharmacologic and non-pharmacologic strategies in mitigating the key risk factors such as hypertension and dyslipidemia in high-risk populations bodes well for the market. In addition, increasing initiatives by clinicians in screening for microalbuminuria among diabetic populations is anticipated to accentuate the market in the coming years. Recent advances in the currently available laboratory testing methods and semi-quantitative tests are anticipated to open up exciting opportunities for players in the microalbuminuria market.

Regionally, currently North America is a prominent market for microalbuminuria, with a substantial demand for the screening and therapies coming from the countries such as the U.S. and Canada. Several studies being conducted in these nations on understanding the pathophysiological mechanism for the condition and initiatives undertaken by national health agencies on early drug interventions are the key factors boosting the regional market. The soaring morbidity of cardiovascular disease in the U.S. is expected to open up lucrative growth avenues for market players.

Prominent players operating in the microalbuminuria market include Daiichi Sankyo Company, Limited, AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd., Steno Diabetes Center A/S, Alfa Wassermann S.p.A, Sanofi S.A., and Novartis International AG.